Fig. 2.

Effects of RANBP9 abrogation on NSCLC cells proliferation and sensitivity to cisplatin. a Growth curve of RANBP9 WT and KO clones showing the lower proliferation rate of cells lacking in RANBP9 expression. Data are representative of two independent experiments performed in triplicate. b Cell cycle analysis by flow cytometry of propidium iodide stained cells. Red peaks indicate G1 and G2 phase, stripes indicate S phase. Cells were treated with nocodazole 200 ng/mL for 24 h to induce G2-blockage in order to identify the percentage of cells moving from G1 to G2 phase. Data are representative of two independent experiments. c CDDP IC50 calculation on RANBP9 WT16 (C, IC50: 26.9 μM) and KO2 (D, IC50: 12.7 μM) clones. Data are representative of two independent experiments. d Colony assay and quantification of A549 RANBP9 WT and KO clones left untreated (NT) or treated with the indicated dose of CDDP for 24 h. Cells were allowed to grow for 8 days and then colonies were stained and counted. The average colony number normalized for the NT ± SD is reported. *p-value < 0.05, **p-value < 0.01. Data are representative of two independent experiments performed in triplicate